PLCO vs Brock Lung Cancer Risk Calculators

1. Start With The Clinical Question

Lung cancer risk calculators are often grouped together, but they do not all belong at the same point in the pathway. The safest way to choose between PLCOm2012, Brock, Mayo, Herder, and Lung-RADS is to first ask what information is already available.

This distinction matters because mixing pre-screening risk and post-detection nodule risk can create false reassurance or unnecessary escalation. A patient may have a modest baseline PLCOm2012 risk but still need careful evaluation of a suspicious nodule, and a high PLCOm2012 risk does not make every small nodule malignant.

2. Calculator Comparison Table

3. PLCOm2012 vs Brock: Different Denominators

PLCOm2012 estimates the chance that an eligible person will develop lung cancer over a 6-year horizon. It was developed from the PLCO trial cohort and is commonly discussed as a more individualized alternative to age-plus-pack-year screening rules. It is useful before LDCT because it incorporates demographic, medical, and smoking variables that fixed thresholds cannot capture.

Brock, also called the PanCan model, starts later in the pathway. It estimates the probability that a specific CT-detected pulmonary nodule is malignant. The nodule is the unit of assessment. That is why nodule morphology, attenuation, size, spiculation, location, and number of nodules become central.

4. Where Mayo, Herder, And Lung-RADS Fit

Mayo and Brock both estimate pulmonary nodule malignancy probability, but their inputs and original clinical contexts differ. Mayo is often useful for a solitary pulmonary nodule in general clinical practice, while Brock is especially helpful for CT-screening-detected nodules and multiple-nodule contexts. If PET-CT has already been performed, the Herder model can incorporate FDG uptake and move the estimate from pretest probability to post-PET probability.

Lung-RADS is not a malignancy-probability equation in the same sense. It is a reporting and management framework for lung cancer screening CT. In a screening program, Lung-RADS provides the language for radiology categories, while Brock or another probability model may help a multidisciplinary team contextualize risk in selected nodules.

5. Practical Workflow Guidance

1. At screening referral: calculate PLCOm2012, check age and smoking history against local screening policy, and confirm that the patient is fit enough and willing to undergo downstream evaluation if cancer is found.
2. At LDCT result review: assign or confirm Lung-RADS category, compare with prior imaging, and document whether the finding is new, stable, or growing.
3. For an indeterminate nodule: use Brock or Mayo as structured pretest probability support.
4. After PET-CT: use Herder if the clinical pathway calls for PET-refined probability estimation.
5. At tumor board: combine calculator outputs with surgical fitness, pulmonary reserve, competing diagnoses, patient preference, procedural risk, and local guideline pathways before recommending surveillance, biopsy, ablation, surgery, or systemic work-up.

The OncoToolkit lung cancer hub groups these tools with staging, prognostic, and immunotherapy indices so that screening and nodule workflows are not isolated from the rest of thoracic oncology care.

6. Common Pitfalls

• Using old smoking history data: pack-years, years since quitting, and smoking duration are frequently mis-entered. Reconcile the smoking history before calculating PLCOm2012.
• Ignoring prior imaging: nodule growth and stability can change management even when a one-time probability score looks reassuring.
• Applying nodule models to the wrong lesion type: models may perform differently for subsolid nodules, inflammatory lesions, post-infectious scarring, or known extrapulmonary cancer.
• Treating thresholds as orders: model outputs should trigger structured discussion, not automatic biopsy or discharge from follow-up.
• Forgetting patient-centered feasibility: screening is most useful when the patient could reasonably complete diagnostic evaluation and potentially curative treatment if cancer is detected.

7. Frequently Asked Questions